Review paper
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Abstract
The past decade in hepatology has witnessed great victories in the treatment of viral hepatitis and resounding failures in nonalcoholic steatohepatitis (NASH). This is sobering, given the global shift in the burden of disease from viral hepatitis toward NASH. Key therapeutic casualties in NASH have included simtuzumab,1Harrison S.A. Abdelmalek M.F. Caldwell S. et al.Simtuzumab is ineffective for patients with bridging fibrosis or compensated...
Paper Details
Title
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Published Date
Jul 1, 2023
Journal
Volume
165
Issue
1
Pages
5 - 10
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History